Literature DB >> 30362844

Personalized vaccination against ovarian cancer: what are the possibilities?

Janos L Tanyi1, Erin George1.   

Abstract

Entities:  

Keywords:  Cancer vaccine; immunotherapy; neo-antigens; ovarian cancer; personalized vaccine

Mesh：

Substances：

Year:  2018        PMID： 30362844      PMCID： PMC6592278          DOI： 10.1080/14760584.2018.1541743

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


× No keyword cloud information.
  25 in total

Review 1.  Whole tumor antigen vaccines.

Authors:  Cheryl Lai-Lai Chiang; Fabian Benencia; George Coukos
Journal:  Semin Immunol       Date:  2010-03-30       Impact factor: 11.130

2.  Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.

Authors:  Robert O Dillman; Andrew N Cornforth; Carol Depriest; Edward F McClay; Thomas T Amatruda; Cristina de Leon; Robin E Ellis; Cheryl Mayorga; Denysha Carbonell; James M Cubellis
Journal:  J Immunother       Date:  2012-10       Impact factor: 4.456

Review 3.  T-regulatory cells: key players in tumor immune escape and angiogenesis.

Authors:  Andrea Facciabene; Gregory T Motz; George Coukos
Journal:  Cancer Res       Date:  2012-05-01       Impact factor: 12.701

Review 4.  Cancer/testis antigens, gametogenesis and cancer.

Authors:  Andrew J G Simpson; Otavia L Caballero; Achim Jungbluth; Yao-Tseng Chen; Lloyd J Old
Journal:  Nat Rev Cancer       Date:  2005-08       Impact factor: 60.716

5.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.

Authors:  Roel G W Verhaak; Pablo Tamayo; Ji-Yeon Yang; Diana Hubbard; Hailei Zhang; Chad J Creighton; Sian Fereday; Michael Lawrence; Scott L Carter; Craig H Mermel; Aleksandar D Kostic; Dariush Etemadmoghadam; Gordon Saksena; Kristian Cibulskis; Sekhar Duraisamy; Keren Levanon; Carrie Sougnez; Aviad Tsherniak; Sebastian Gomez; Robert Onofrio; Stacey Gabriel; Lynda Chin; Nianxiang Zhang; Paul T Spellman; Yiqun Zhang; Rehan Akbani; Katherine A Hoadley; Ari Kahn; Martin Köbel; David Huntsman; Robert A Soslow; Anna Defazio; Michael J Birrer; Joe W Gray; John N Weinstein; David D Bowtell; Ronny Drapkin; Jill P Mesirov; Gad Getz; Douglas A Levine; Matthew Meyerson
Journal:  J Clin Invest       Date:  2012-12-21       Impact factor: 14.808

6.  Hypochlorous acid: a natural adjuvant that facilitates antigen processing, cross-priming, and the induction of adaptive immunity.

Authors:  Zofia M Prokopowicz; Frederick Arce; Rafal Biedroń; Cheryl L-L Chiang; Marta Ciszek; David R Katz; Maria Nowakowska; Szczepan Zapotoczny; Janusz Marcinkiewicz; Benjamin M Chain
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

7.  Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients.

Authors:  Rajasekharan Somasundaram; Rolf Swoboda; Laura Caputo; Laszlo Otvos; Barbara Weber; Patricia Volpe; Patricia van Belle; Susan Hotz; David E Elder; Francesco M Marincola; Lynn Schuchter; DuPont Guerry; Brian J Czerniecki; Dorothee Herlyn
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

Review 8.  Cancer immunotherapy with mRNA-transfected dendritic cells.

Authors:  Eli Gilboa; Johannes Vieweg
Journal:  Immunol Rev       Date:  2004-06       Impact factor: 12.988

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes.

Authors:  Shigeo Koido; Sadamu Homma; Masato Okamoto; Yoshihisa Namiki; Kazuki Takakura; Akitaka Takahara; Shunichi Odahara; Shintaro Tsukinaga; Toyokazu Yukawa; Jimi Mitobe; Hiroshi Matsudaira; Keisuke Nagatsuma; Kan Uchiyama; Mikio Kajihara; Seiji Arihiro; Hiroo Imazu; Hiroshi Arakawa; Shin Kan; Hideo Komita; Masaki Ito; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240
View more
  2 in total

1.  Advanced cell therapeutics are changing the clinical landscape: will mesenchymal stromal cells be a part of it?

Authors:  Richard Schäfer
Journal:  BMC Med       Date:  2019-03-05       Impact factor: 8.775

Review 2.  Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.

Authors:  Chang Yang; Bai-Rong Xia; Zhao-Cong Zhang; Yong-Jian Zhang; Ge Lou; Wei-Lin Jin
Journal:  Front Immunol       Date:  2020-10-06       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.